menu search

STVN / Stevanato Group: Undeniable Quality, But Lacking Upside

Stevanato Group: Undeniable Quality, But Lacking Upside
Stevenato Group is a Pharmaceutical Manufacturing leader, generating 15% net income margins annually. The company has developed a global customer base over the course of its 70-year operating history and continues to add new clients with each passing quarter. The current valuation appears to be maxed out, but potential investors should add this high-quality company to their watchlists. Read More
Posted: Jun 14 2023, 04:21
Author Name: Seeking Alpha
Views: 101859

STVN News  

Stevanato Group S.p.A. (STVN) Q3 2023 Earnings Call Transcript

By Seeking Alpha
October 31, 2023

Stevanato Group S.p.A. (STVN) Q3 2023 Earnings Call Transcript

Stevanato Group S.p.A. (STVN) Q3 2023 Earnings Call Transcript more_horizontal

TAK vs. STVN: Which Stock Is the Better Value Option?

By Zacks Investment Research
October 27, 2023

TAK vs. STVN: Which Stock Is the Better Value Option?

Investors interested in stocks from the Medical - Drugs sector have probably already heard of Takeda Pharmaceutical Co. (TAK) and Stevanato Group (STV more_horizontal

USNA or STVN: Which Is the Better Value Stock Right Now?

By Zacks Investment Research
October 11, 2023

USNA or STVN: Which Is the Better Value Stock Right Now?

Investors looking for stocks in the Medical - Drugs sector might want to consider either USANA Health Sciences (USNA) or Stevanato Group (STVN). But w more_horizontal

Stevanato: Secular Tailwinds In Biologics Support Downstream Demand

By Seeking Alpha
September 15, 2023

Stevanato: Secular Tailwinds In Biologics Support Downstream Demand

Stevanato Group is a global provider of drug containment with a CAPEX growth plan to support growth and reach new geographical diversification. Balanc more_horizontal

All You Need to Know About Stevanato (STVN) Rating Upgrade to Buy

By Zacks Investment Research
September 11, 2023

All You Need to Know About Stevanato (STVN) Rating Upgrade to Buy

Stevanato (STVN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the more_horizontal

Strength Seen in Stevanato (STVN): Can Its 5.0% Jump Turn into More Strength?

By Zacks Investment Research
June 19, 2023

Strength Seen in Stevanato (STVN): Can Its 5.0% Jump Turn into More Strength?

Stevanato (STVN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help th more_horizontal

Stevanato Group: Undeniable Quality, But Lacking Upside

By Seeking Alpha
June 14, 2023

Stevanato Group: Undeniable Quality, But Lacking Upside

Stevenato Group is a Pharmaceutical Manufacturing leader, generating 15% net income margins annually. The company has developed a global customer base more_horizontal

Stevanato Group to Present at Upcoming Investor Conferences

By Business Wire
May 24, 2023

Stevanato Group to Present at Upcoming Investor Conferences

PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnost more_horizontal


Search within

Pages Search Results: